{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:47:45Z","timestamp":1785764865840,"version":"3.56.0"},"reference-count":167,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Italian Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","award":["Project FFC#8\/2021"],"award-info":[{"award-number":["Project FFC#8\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Project FFC#8\/2021"],"award-info":[{"award-number":["Project FFC#8\/2021"]}],"id":[{"id":"https:\/\/ror.org\/01engnx74","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Pasteur Institute Cenci Bolognetti Foundation","award":["project 2022\u20132023 Anna Tramontano (call 2020)"],"award-info":[{"award-number":["project 2022\u20132023 Anna Tramontano (call 2020)"]}]},{"award":["project 2022\u20132023 Anna Tramontano (call 2020)"],"award-info":[{"award-number":["project 2022\u20132023 Anna Tramontano (call 2020)"]}],"id":[{"id":"https:\/\/ror.org\/051v7w268","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Sapienza Research Projects 2021","award":["2022FRSS2H"],"award-info":[{"award-number":["2022FRSS2H"]}]},{"name":"Sapienza Research Projects 2021","award":["B53D23020270006"],"award-info":[{"award-number":["B53D23020270006"]}]},{"award":["2022FRSS2H"],"award-info":[{"award-number":["2022FRSS2H"]}],"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}]},{"award":["B53D23020270006"],"award-info":[{"award-number":["B53D23020270006"]}],"id":[{"id":"https:\/\/ror.org\/02be6w209","id-type":"ROR","asserted-by":"publisher"}]},{"name":"PRIN 2022","award":["2022FRSS2H"],"award-info":[{"award-number":["2022FRSS2H"]}]},{"name":"PRIN 2022","award":["B53D23020270006"],"award-info":[{"award-number":["B53D23020270006"]}]},{"award":["2022FRSS2H"],"award-info":[{"award-number":["2022FRSS2H"]}],"id":[{"id":"https:\/\/ror.org\/0341vw408","id-type":"ROR","asserted-by":"publisher"}]},{"award":["B53D23020270006"],"award-info":[{"award-number":["B53D23020270006"]}],"id":[{"id":"https:\/\/ror.org\/0341vw408","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Cystic fibrosis (CF) is one of the most common rare genetic diseases. It is caused by pathogenic variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. More than 2200 variants have been identified in the CFTR gene that need detailed knowledge and functional characterization in order to develop specific therapeutic strategies. The traditional therapy for CF relied on addressing symptoms through mucolytic and antibiotic treatments, respiratory physiotherapy and aerosol therapy. However, in the last few years, the development of small new molecules targeting and restoring the underlying CFTR channel defect marked an important step in CF treatment. In addition, the implementation of patient-specific cellular models allowed the evaluation of pharmacological responses, leading to therapeutic advances in the direction of personalized treatment. The focus of this review is to describe and discuss the strategies for restoring the CFTR functional defects depending on the specific CFTR pathogenic variants. In particular, the review highlights the possible application of experimental and clinical drugs to CF treatment, which may allow improvements in patients\u2019 quality of life and life expectancy. The in vitro testing of therapeutic drugs (theratyping) is performed nowadays through the use of several cellular models, especially those derived from patient-specific tissues. This topic is a hot point in CF research and the review also aims to provide an overview of the state of the art in theratyping. The novelty of this review is the integrated view of the most recent achievements in precision diagnostics and therapy of CF at the molecular, cellular and clinical level, which are able to change the natural history of this disease.<\/jats:p>","DOI":"10.3390\/ijms27156919","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:57:56Z","timestamp":1785761876000},"page":"6919","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1432-1226","authenticated-orcid":false,"given":"Sara","family":"Allushi","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0435-0765","authenticated-orcid":false,"given":"Mariarita","family":"Virgulti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-820X","authenticated-orcid":false,"given":"Giovanna","family":"Blacon\u00e0","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-4071","authenticated-orcid":false,"given":"Giampiero","family":"Ferraguti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Eramo","sequence":"additional","affiliation":[{"name":"Department of Oncology and Molecular Medicine, Italian Institute of Health, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-2494","authenticated-orcid":false,"given":"Marco","family":"Lucarelli","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy"},{"name":"Pasteur Institute Cenci Bolognetti Foundation, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","article-title":"Structure and Function of the CFTR Chloride Channel","volume":"79","author":"Sheppard","year":"1999","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.lpm.2017.04.010","article-title":"The Diagnosis of Cystic Fibrosis","volume":"46","author":"Vermeulen","year":"2017","journal-title":"Presse Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic Fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic Fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ejhg.2008.136","article-title":"Best Practice Guidelines for Molecular Genetic Diagnosis of Cystic Fibrosis and CFTR-Related Disorders\u2013Updated European Recommendations","volume":"17","author":"Dequeker","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1377","DOI":"10.1542\/peds.2014-2081","article-title":"Inconclusive Diagnosis of Cystic Fibrosis after Newborn Screening","volume":"135","author":"Ooi","year":"2015","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.1992.03480130110034","article-title":"Congenital Bilateral Absence of the Vas Deferens. A Primarily Genital Form of Cystic Fibrosis","volume":"267","author":"Anguiano","year":"1992","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105267","DOI":"10.1016\/j.phrs.2020.105267","article-title":"Cystic Fibrosis: Physiopathology and the Latest Pharmacological Treatments","volume":"162","author":"Fonseca","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_10","unstructured":"Sankari, A., and Sharma, S. (2024). Cystic Fibrosis. StatPearls, StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1542\/peds.23.3.545","article-title":"A Test for Concentration of Electrolytes in Sweat in Cystic Fibrosis of the Pancreas Utilizing Pilocarpine by Iontophoresis","volume":"23","author":"Gibson","year":"1959","journal-title":"Pediatrics"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019Hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide Rates of Diagnosis and Effective Treatment for Cystic Fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2119\/molmed.2014.00229","article-title":"A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis","volume":"21","author":"Lucarelli","year":"2015","journal-title":"Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ng0496-348","article-title":"Complexity in a Monogenic Disease","volume":"12","author":"Estivill","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR Mutation Classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_17","unstructured":"Zolin, A., Adamoli, A., Zomer, D., Fox, A., Krasnyk, M., Lorca Mayor, S., Prasad, V., Gambazza, S., Orenti, A., and Gkolia, P. (2026). European Cystic Fibrosis Society Patient Registry, 2024 Annual Data Report, European Cystic Fibrosis Society (ECFS)."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in Therapies for Cystic Fibrosis","volume":"4","author":"Amaral","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR Biology toward Combinatorial Pharmacotherapy: Expanded Classification of Cystic Fibrosis Mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101544","DOI":"10.1016\/j.xcrm.2024.101544","article-title":"Prime Editing Functionally Corrects Cystic Fibrosis-Causing CFTR Mutations in Human Organoids and Airway Epithelial Cells","volume":"5","author":"Bulcaen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.adk9428","article-title":"In Vivo Editing of Lung Stem Cells for Durable Gene Correction in Mice","volume":"384","author":"Sun","year":"2024","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114053","DOI":"10.1016\/j.jconrel.2025.114053","article-title":"Lung Tissue-Optimized Gene Editing in Human Cystic Fibrosis Models Following Topical Application of Lipid Nanoparticles","volume":"385","author":"Tafech","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1164\/rccm.202402-0389CI","article-title":"Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial","volume":"210","author":"Davies","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2301683","DOI":"10.1183\/13993003.01683-2023","article-title":"Pharmacological and Pre-Clinical Safety Profile of RSIV.F\/HN, a Hybrid Lentiviral Vector for Cystic Fibrosis Gene Therapy","volume":"65","author":"Moiseenko","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_25","first-page":"S80","article-title":"P045 LenticlairTM 1: A Phase 1\/2 Trial Evaluating the Safety, Tolerability and Efficacy of an Inhaled F\/HN-Pseudotyped Lentiviral Vector for CF Gene Therapy in People with CF Ineligible for CFTR Modulators","volume":"23","author":"Davies","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_26","first-page":"S80","article-title":"P046 LenticlairTM-ON: An Extension Trial Examining Long-Term Safety and Efficacy Outcomes Associated with an Inhaled F\/HN-Pseudotyped Lentiviral Vector for CF Gene Therapy in People with Cystic Fibrosis","volume":"23","author":"Davies","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic Ataluren (PTC124) Treatment of Nonsense Mutation Cystic Fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","article-title":"Effectiveness of PTC124 Treatment of Cystic Fibrosis Caused by Nonsense Mutations: A Prospective Phase II Trial","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2020.01.007","article-title":"Efficacy and Safety of Ataluren in Patients with Nonsense-Mutation Cystic Fibrosis Not Receiving Chronic Inhaled Aminoglycosides: The International, Randomized, Double-Blind, Placebo-Controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)","volume":"19","author":"Konstan","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"L756","DOI":"10.1152\/ajplung.00038.2023","article-title":"The Synthetic Aminoglycoside ELX-02 Induces Readthrough of G550X-CFTR Producing Superfunctional Protein That Can Be Further Enhanced by CFTR Modulators","volume":"324","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR Nonsense Alleles with ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/17425255.2023.2266361","article-title":"The Safety and Toxicity Profile of SPL84, an Inhaled Antisense Oligonucleotide for Treatment of Cystic Fibrosis Patients with the 3849 +10kb C->T Mutation, Supports a Phase 1\/2 Clinical Study","volume":"19","author":"Friedman","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcf.2024.10.004","article-title":"A Phase I Study Assessing the Safety and Tolerability of SPL84, an Inhaled Antisense Oligonucleotide for Treatment of Cystic Fibrosis Patients with the 3849 +10kb C->T","volume":"24","author":"Caraco","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/nat.2023.0015","article-title":"Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849\u2009+\u200910\u2009Kb C->T Cystic Fibrosis Patients","volume":"33","author":"Friedman","year":"2023","journal-title":"Nucleic Acid. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semcdb.2017.08.053","article-title":"Beyond Quality Control: The Role of Nonsense-Mediated MRNA Decay (NMD) in Regulating Gene Expression","volume":"75","author":"Nasif","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1101\/gad.913001","article-title":"Human SMG-1, a Novel Phosphatidylinositol 3-Kinase-Related Protein Kinase, Associates with Components of the MRNA Surveillance Complex and Is Involved in the Regulation of Nonsense-Mediated MRNA Decay","volume":"15","author":"Yamashita","year":"2001","journal-title":"Genes Dev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.bmcl.2012.08.107","article-title":"Identification of Pyrimidine Derivatives as HSMG-1 Inhibitors","volume":"22","author":"Gopalsamy","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"RP95952","DOI":"10.7554\/eLife.95952","article-title":"Identification of Nonsense-Mediated Decay Inhibitors That Alter the Tumor Immune Landscape","volume":"13","author":"Cook","year":"2025","journal-title":"Elife"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1083\/jcb.200611086","article-title":"Inhibition of Nonsense-Mediated MRNA Decay (NMD) by a New Chemical Molecule Reveals the Dynamic of NMD Factors in P-Bodies","volume":"178","author":"Durand","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/0008-5472.CAN-13-2235","article-title":"Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense P53 Mutations","volume":"74","author":"Martin","year":"2014","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cheruiyot, A., Li, S., Nickless, A., Roth, R., Fitzpatrick, J.A.J., and You, Z. (2018). Compound C Inhibits Nonsense-Mediated RNA Decay Independently of AMPK. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204978"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1750-1172-7-58","article-title":"Rescue of Nonsense Mutations by Amlexanox in Human Cells","volume":"7","author":"Beghyn","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Benslimane, N., Miressi, F., Loret, C., Richard, L., Nizou, A., Pyromali, I., Faye, P.-A., Favreau, F., Lejeune, F., and Lia, A.-S. (2023). Amlexanox: Readthrough Induction and Nonsense-Mediated MRNA Decay Inhibition in a Charcot-Marie-Tooth Model of HiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071034"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"McHugh, D.R., Cotton, C.U., and Hodges, C.A. (2020). Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010344"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108058","DOI":"10.1016\/j.carres.2020.108058","article-title":"Chemical Modifications of G418 (Geneticin): Synthesis of Novel Readthrough Aminoglycosides Results in an Improved in Vitro Safety Window but No Improvements in Vivo","volume":"495","author":"Baiazitov","year":"2020","journal-title":"Carbohydr. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR Trafficking and Gating in Human Cystic Fibrosis Airway Primary Cultures by Small Molecules","volume":"290","author":"Straley","year":"2006","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF Airway Epithelial Cell Function in Vitro by a CFTR Potentiator, VX-770","volume":"106","author":"Hadida","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR Protein Processing Defect in Vitro by the Investigational Drug VX-809","volume":"108","author":"Hadida","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0042-1758851","article-title":"CFTR Modulators: Current Status and Evolving Knowledge","volume":"44","author":"Regard","year":"2023","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17476348.2020.1682998","article-title":"Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis","volume":"14","author":"Paterson","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_52","first-page":"CD009841","article-title":"Potentiators (Specific Therapies for Class III and IV Mutations) for Cystic Fibrosis","volume":"1","author":"Skilton","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and Safety of Ivacaftor in Patients with Cystic Fibrosis and a Non-G551D Gating Mutation","volume":"13","author":"Munck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and Safety of Ivacaftor in Patients with Cystic Fibrosis Who Have an Arg117His-CFTR Mutation: A Double-Blind, Randomised Controlled Trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor Potentiation of Multiple CFTR Channels with Gating Mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s41030-020-00129-2","article-title":"Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations","volume":"6","author":"Pilewski","year":"2020","journal-title":"Pulm. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor Treatment of Cystic Fibrosis in Children Aged 12 to <24 Months and with a CFTR Gating Mutation (ARRIVAL): A Phase 3 Single-Arm Study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in Subjects with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"Lumacaftor\/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and Safety of Lumacaftor and Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis Homozygous for F508del-CFTR: A Randomised, Placebo-Controlled Phase 3 Trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Lumacaftor and Ivacaftor Combination Therapy in Children Aged 2-5 Years with Cystic Fibrosis Homozygous for F508del-CFTR: An Open-Label Phase 3 Study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-Term Safety and Efficacy of Lumacaftor-Ivacaftor Therapy in Children Aged 6-11 Years with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation: A Phase 3, Open-Label, Extension Study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A Phase 3, Open-Label Study of Lumacaftor\/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR Corrector (Lumacaftor) and a CFTR Potentiator (Ivacaftor) for Treatment of Patients with Cystic Fibrosis Who Have a Phe508del CFTR Mutation: A Phase 2 Randomised Controlled Trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1513\/AnnalsATS.201701-058OC","article-title":"An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor\/Ivacaftor","volume":"14","author":"Jennings","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR Correction by Type I Folding Correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 Corrects Folding Defects in Cystic Fibrosis Transmembrane Conductance Regulator Protein through Action on Membrane-Spanning Domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcf.2020.04.015","article-title":"Tezacaftor\/Ivacaftor in People with Cystic Fibrosis Heterozygous for Minimal Function CFTR Mutations","volume":"19","author":"Munck","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Bongiorno, R., Ludovico, A., Moran, O., and Baroni, D. (2023). Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612838"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation: A Double-Blind, Randomised, Phase 3 Trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged \u2a7e6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular Structures Reveal Synergistic Rescue of \u0394508 CFTR by Trikafta Modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(24)00142-5","article-title":"WS06.03 Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor (ELX\/TEZ\/IVA) in People with Cystic Fibrosis and ELX\/TEZ\/IVA-Responsive, Non-F508del Genotypes: A Phase 3, Randomised, Placebo-Controlled Trial","volume":"23","author":"Castellani","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Programme of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis with Advanced Lung Disease and No F508del CFTR Variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of Elexacaftor-Tezacaftor-Ivacaftor Treatment in Individuals with Cystic Fibrosis and CFTR(N1303K) in the USA: A Prospective, Multicentre, Open-Label, Single-Arm Trial","volume":"12","author":"Solomon","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-Tezacaftor-Deutivacaftor versus Elexacaftor-Tezacaftor-Ivacaftor in Individuals with Cystic Fibrosis Aged 12 Years and Older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from Two Randomised, Active-Controlled, Phase 3 Trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and Efficacy of Vanzacaftor-Tezacaftor-Deutivacaftor in Adults with Cystic Fibrosis: Randomised, Double-Blind, Controlled, Phase 2 Trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-Tezacaftor-Deutivacaftor for Children Aged 6-11 Years with Cystic Fibrosis (RIDGELINE Trial VX21-121-105): An Analysis from a Single-Arm, Phase 3 Trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2402443","DOI":"10.1183\/13993003.02443-2024","article-title":"Cystic Fibrosis Microbiome-Directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a Multicentre Randomised Controlled Trial","volume":"66","author":"Plant","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2025.11.014","article-title":"Improvements in Health-Related Quality of Life in People with Cystic Fibrosis \u22656 Years of Age Treated with Vanzacaftor\/Tezacaftor\/Deutivacaftor","volume":"25","author":"Wainwright","year":"2026","journal-title":"J. Cyst. Fibros."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1038\/s41598-023-34440-0","article-title":"Novel Tricyclic Pyrrolo-Quinolines as Pharmacological Correctors of the Mutant CFTR Chloride Channel","volume":"13","author":"Renda","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1021\/acs.jmedchem.1c01897","article-title":"Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives","volume":"65","author":"Brusa","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers Co-Translationally Enhance CFTR Biosynthesis via PCBP1-Mediated Regulation of CFTR MRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi\u00ae and Amplifier Co-Therapy Improves Function from a Rare CFTR Mutation in Gene-Edited Cells and Patient Tissue","volume":"9","author":"Molinski","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12154","DOI":"10.1074\/jbc.M707610200","article-title":"The Mechanism of Cystic Fibrosis Transmembrane Conductance Regulator Transcriptional Repression during the Unfolded Protein Response","volume":"283","author":"Bartoszewski","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1101\/gr.073817.107","article-title":"Detection and Characterization of Silencers and Enhancer-Blockers in the Greater CFTR Locus","volume":"18","author":"Petrykowska","year":"2008","journal-title":"Genome Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1042\/BJ20070282","article-title":"The Epigenetic Signature of CFTR Expression Is Co-Ordinated via Chromatin Acetylation through a Complex Intronic Element","volume":"408","author":"Paul","year":"2007","journal-title":"Biochem. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/hmg\/ddv032","article-title":"CHD6 Regulates the Topological Arrangement of the CFTR Locus","volume":"24","author":"Sancho","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/epi.27696","article-title":"Chromatin Remodeling Mediated by the FOXA1\/A2 Transcription Factors Activates CFTR Expression in Intestinal Epithelial Cells","volume":"9","author":"Kerschner","year":"2014","journal-title":"Epigenetics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.4161\/epi.28967","article-title":"A Balance between Activating and Repressive Histone Modifications Regulates Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Expression in Vivo","volume":"9","author":"Bergougnoux","year":"2014","journal-title":"Epigenetics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"110350","DOI":"10.1016\/j.ygeno.2022.110350","article-title":"Cross-Talk between Enhancers, Structural Elements and Activating Transcription Factors Maintains the 3D Architecture and Expression of the CFTR Gene","volume":"114","author":"Yin","year":"2022","journal-title":"Genomics"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Blotas, C., F\u00e9rec, C., and Moisan, S. (2023). Tissue-Specific Regulation of CFTR Gene Expression. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310678"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2016.11.023","article-title":"Epigenetic Regulation of CFTR in Salivary Gland","volume":"481","author":"Shin","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.ajpath.2014.12.022","article-title":"New Insights about MiRNAs in Cystic Fibrosis","volume":"185","author":"Sonneville","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/CBI20100664","article-title":"MicroRNAs and Cystic Fibrosis--an Epigenetic Perspective","volume":"35","author":"Xu","year":"2011","journal-title":"Cell Biol. Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/dna.1995.14.811","article-title":"Methylation Status of CpG Sites in the Mouse and Human CFTR Promoters","volume":"14","author":"Denamur","year":"1995","journal-title":"DNA Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1165\/rcmb.2009-0149OC","article-title":"Multiple Mechanisms Influence Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Gene Promoter","volume":"43","author":"Lewandowska","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13023-023-02807-1","article-title":"Exploring the Methylation Status of CFTR and PKIA Genes as Potential Biomarkers for Lung Adenocarcinoma","volume":"18","author":"Xu","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/cbin.11260","article-title":"Promoter Hypermethylation of the CFTR Gene as a Novel Diagnostic and Prognostic Marker of Breast Cancer","volume":"44","author":"Liu","year":"2020","journal-title":"Cell Biol. Int."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Shin, Y., Kim, M., Won, J., Kim, J., Oh, S.B., Lee, J.-H., and Park, K. (2020). Epigenetic Modification of CFTR in Head and Neck Cancer. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030734"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1440-1843.2011.01994.x","article-title":"Promoter Hypermethylation of the CFTR Gene and Clinical\/Pathological Features Associated with Non-Small Cell Lung Cancer","volume":"16","author":"Son","year":"2011","journal-title":"Respirology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/1389450116666150416114514","article-title":"Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease","volume":"16","author":"Sirinupong","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA Methylation: Islands, Start Sites, Gene Bodies and Beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-54490-3_19","article-title":"5-Azacytidine\/5-Azacitidine","volume":"201","author":"Florek","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.seminhematol.2012.08.001","article-title":"Clinical Results with the DNA Hypomethylating Agent 5-Aza-2\u2019-Deoxycytidine (Decitabine) in Patients with Myelodysplastic Syndromes: An Update","volume":"49","author":"Joeckel","year":"2012","journal-title":"Semin. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1139\/o88-119","article-title":"Effect of 3-Deazaadenosine on Methionine Metabolism in Isolated Perfused Livers","volume":"66","author":"Duerre","year":"1988","journal-title":"Biochem. Cell Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/0006-2952(90)90720-6","article-title":"Influence of S-Adenosylhomocysteine Hydrolase Inhibitors on S-Adenosylhomocysteine and S-Adenosylmethionine Pool Levels in L929 Cells","volume":"40","author":"Cools","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.4161\/cc.9.19.13193","article-title":"Early Demethylation of Non-CpG, CpC-Rich, Elements in the Myogenin 5\u2019-Flanking Region: A Priming Effect on the Spreading of Active Demethylation","volume":"9","author":"Fuso","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1074\/jbc.M008234200","article-title":"The Dynamics of Myogenin Site-Specific Demethylation Is Strongly Correlated with Its Expression and with Muscle Differentiation","volume":"276","author":"Lucarelli","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/1097-4644(20010601)81:3<401::AID-JCB1054>3.0.CO;2-U","article-title":"Erythroid Differentiation and Regulatory Gene Expression Are Modulated by Adenosine Derivatives Interfering with S-Adenosylmethionine Metabolic Pathway","volume":"81","author":"Scarpa","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Fukuda, R., and Okiyoneda, T. (2018). Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01100"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jcf.2017.01.009","article-title":"Pharmacokinetics and Safety of Cavosonstat (N91115) in Healthy and Cystic Fibrosis Adults Homozygous for F508DEL-CFTR","volume":"16","author":"Donaldson","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Taniguchi, S., Ito, Y., Kiritani, H., Maruo, A., Sakai, R., Ono, Y., Fukuda, R., and Okiyoneda, T. (2022). The Ubiquitin Ligase RNF34 Participates in the Peripheral Quality Control of CFTR (RNF34 Role in CFTR PeriQC). Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.840649"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.devcel.2018.02.001","article-title":"Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase","volume":"44","author":"Okiyoneda","year":"2018","journal-title":"Dev. Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic Fibrosis Genetics: From Molecular Understanding to Clinical Application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/MCP.0000000000000521","article-title":"Theratyping in Cystic Fibrosis","volume":"24","author":"Crawford","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","article-title":"A Revised Airway Epithelial Hierarchy Includes CFTR-Expressing Ionocytes","volume":"560","author":"Montoro","year":"2018","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","article-title":"A Single-Cell Atlas of the Airway Epithelium Reveals the CFTR-Rich Pulmonary Ionocyte","volume":"560","author":"Plasschaert","year":"2018","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.202008-3198OC","article-title":"Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia","volume":"203","author":"Okuda","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6150-4-31","article-title":"Multipotent Adult Germ-Line Stem Cells, like Other Pluripotent Stem Cells, Can Be Killed by Cytotoxic T Lymphocytes despite Low Expression of Major Histocompatibility Complex Class I Molecules","volume":"4","author":"Dressel","year":"2009","journal-title":"Biol. Direct"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jcp.21948","article-title":"Genome Modification in Human Embryonic Stem Cells","volume":"222","author":"Tenzen","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ijc.31260","article-title":"Conditionally Reprogrammed Cells (CRC) Methodology Does Not Allow the in Vitro Expansion of Patient-Derived Primary and Metastatic Lung Cancer Cells","volume":"143","author":"Sette","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1172\/JCI42297","article-title":"Human Keratinocytes Are Efficiently Immortalized by a Rho Kinase Inhibitor","volume":"120","author":"Chapman","year":"2010","journal-title":"J. Clin. Invest."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0076-6879(00)25449-9","article-title":"Use and Properties of ROCK-Specific Inhibitor Y-27632","volume":"325","author":"Narumiya","year":"2000","journal-title":"Methods Enzymol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1523-1747.2000.00884.x","article-title":"Adhesive Properties of Human Basal Epidermal Cells: An Analysis of Keratinocyte Stem Cells, Transit Amplifying Cells, and Postmitotic Differentiating Cells","volume":"114","author":"Kaur","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"20035","DOI":"10.1073\/pnas.1213241109","article-title":"Conditionally Reprogrammed Cells Represent a Stem-like State of Adult Epithelial Cells","volume":"109","author":"Suprynowicz","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and Drug Administration\u2019s Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2100908","DOI":"10.1183\/13993003.00908-2021","article-title":"Theratyping Cystic Fibrosis in Vitro in ALI Culture and Organoid Models Generated from Patient-Derived Nasal Epithelial Conditionally Reprogrammed Stem Cells","volume":"58","author":"Sette","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_140","first-page":"e50646","article-title":"Culturing of Human Nasal Epithelial Cells at the Air Liquid Interface","volume":"80","author":"Brighton","year":"2013","journal-title":"J. Vis. Exp."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","article-title":"Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells","volume":"19","author":"Mou","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jcf.2020.12.019","article-title":"Significant Functional Differences in Differentiated Conditionally Reprogrammed (CRC)- and Feeder-Free Dual SMAD Inhibited-Expanded Human Nasal Epithelial Cells","volume":"20","author":"Awatade","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1242\/dev.140103","article-title":"Lung Organoids: Current Uses and Future Promise","volume":"144","author":"Barkauskas","year":"2017","journal-title":"Development"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"EMBJ2018100300","DOI":"10.15252\/embj.2018100300","article-title":"Long-Term Expanding Human Airway Organoids for Disease Modeling","volume":"38","author":"Sachs","year":"2019","journal-title":"EMBO J."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Awatade, N.T., Wong, S.L., Hewson, C.K., Fawcett, L.K., Kicic, A., Jaffe, A., and Waters, S.A. (2018). Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01429"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-023-02516-0","article-title":"L1077P CFTR Pathogenic Variant Function Rescue by Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis Patient-Derived Air-Liquid Interface (ALI) Cultures and Organoids: In Vitro Guided Personalized Therapy of Non-F508del Patients","volume":"24","author":"Castelli","year":"2023","journal-title":"Respir. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 Stem Cells Build Crypt-Villus Structures in Vitro without a Mesenchymal Niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A Functional CFTR Assay Using Primary Cystic Fibrosis Intestinal Organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2022.11.007","article-title":"Patient-Derived Cell Models for Personalized Medicine Approaches in Cystic Fibrosis","volume":"22","author":"Ramalho","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Lo Cicero, S., Castelli, G., Ceci, A., Cerio, A.M., Blacon\u00e0, G., Virgulti, M., Allushi, S., Sette, G., Spadaro, F., and Amato, F. (2025). CFTR Modulator Response in Nasal Organoids Derived from People with Cystic Fibrosis. Cells, 14.","DOI":"10.3390\/cells14231914"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e202101320","DOI":"10.26508\/lsa.202101320","article-title":"Measuring Cystic Fibrosis Drug Responses in Organoids Derived from 2D Differentiated Nasal Epithelia","volume":"5","author":"Amatngalim","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"108180","DOI":"10.1016\/j.isci.2023.108180","article-title":"In Silico Analysis and Theratyping of an Ultra-Rare CFTR Genotype (W57G\/A234D) in Primary Human Rectal and Nasal Epithelial Cells","volume":"26","author":"Kleinfelder","year":"2023","journal-title":"iScience"},{"key":"ref_153","first-page":"55159","article-title":"Forskolin-Induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients","volume":"120","author":"Boj","year":"2017","journal-title":"J. Vis. Exp."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1702457","DOI":"10.1183\/13993003.02457-2017","article-title":"Personalised CFTR Pharmacotherapeutic Response Testing and Therapy of Cystic Fibrosis","volume":"51","author":"McCarthy","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.1188302","article-title":"Reconstituting Organ-Level Lung Functions on a Chip","volume":"328","author":"Huh","year":"2010","journal-title":"Science"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nbt.2989","article-title":"Microfluidic Organs-on-Chips","volume":"32","author":"Bhatia","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12938-020-0752-0","article-title":"Organ-on-a-Chip: Recent Breakthroughs and Future Prospects","volume":"19","author":"Wu","year":"2020","journal-title":"Biomed. Eng. Online"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41586-020-2922-4","article-title":"A Molecular Cell Atlas of the Human Lung from Single-Cell RNA Sequencing","volume":"587","author":"Travaglini","year":"2020","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1039\/C4LC01252F","article-title":"A Lung-on-a-Chip Array with an Integrated Bio-Inspired Respiration Mechanism","volume":"15","author":"Stucki","year":"2015","journal-title":"Lab Chip"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.physiol.68.072304.114110","article-title":"Stress Transmission in the Lung: Pathways from Organ to Molecule","volume":"68","author":"Fredberg","year":"2006","journal-title":"Annu. Rev. Physiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human Organs-on-Chips for Disease Modelling, Drug Development and Personalized Medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nmeth.3697","article-title":"Small Airway-on-a-Chip Enables Analysis of Human Lung Inflammation and Drug Responses in Vitro","volume":"13","author":"Benam","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2021.10.004","article-title":"Modeling Pulmonary Cystic Fibrosis in a Human Lung Airway-on-a-Chip","volume":"21","author":"Plebani","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"102148","DOI":"10.1016\/j.mtbio.2025.102148","article-title":"Organoid-on-a-Chip (OrgOC): Advancing Cystic Fibrosis Research","volume":"34","author":"Zheng","year":"2025","journal-title":"Mater. Today Bio"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"103476","DOI":"10.1016\/j.eclinm.2025.103476","article-title":"Elexacaftor-Tezacaftor-Ivacaftor in People with Cystic Fibrosis Harbouring Two CFTR Class I Variants: Real-World Data from the French Compassionate Programme","volume":"88","author":"Burgel","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The Expanded French Compassionate Programme for Elexacaftor-Tezacaftor-Ivacaftor Use in People with Cystic Fibrosis without a F508del CFTR Variant: A Real-World Study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"16805","DOI":"10.1021\/acs.analchem.6c00392","article-title":"Toward precision electrochemical sensing of CFTR function in cystic fibrosis models","volume":"98","author":"Miglione","year":"2026","journal-title":"Anal. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6919\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:06:08Z","timestamp":1785762368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":167,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156919"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156919","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}